OVID THERAPEUTICS INC (OVID) Stock Analyst Ratings
USA - NASDAQ:OVID - US6904691010 - Common Stock
1.35 USD
+0.03 (+2.27%)
1.36 USD
+0.01 (+0.74%)
ChartMill assigns a Buy % Consensus number of 87% to OVID. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.23. This target is 213.56% above the current price.
OVID was analyzed by 14 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about OVID.
In the previous month the buy percentage consensus was at a similar level.
OVID was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-24 | BTIG | Maintains | Buy -> Buy |
| 2025-03-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-01-29 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-18 | BTIG | Maintains | Buy -> Buy |
| 2024-06-18 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-06-18 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-06-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-04-30 | B. Riley Securities | Initiate | Buy |
| 2024-04-29 | HC Wainwright & Co. | Initiate | Buy |
| 2024-04-05 | Wedbush | Initiate | Outperform |
| 2023-12-21 | BTIG | Initiate | Buy |
| 2023-06-14 | JonesTrading | Initiate | Buy |
| 2023-05-02 | Ladenburg Thalmann | Reiterate | Buy |
| 2022-08-29 | Citigroup | Maintains | Neutral |
| 2022-05-20 | Citigroup | Maintains | Neutral |
| 2021-08-25 | Citigroup | Maintains | Neutral |
| 2021-04-20 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
OVID THERAPEUTICS INC / OVID FAQ
What do analysts expect the price target to be for OVID THERAPEUTICS INC (OVID)?
14 analysts have analysed OVID and the average price target is 4.23 USD. This implies a price increase of 213.56% is expected in the next year compared to the current price of 1.35.
Can you provide the consensus rating for OVID THERAPEUTICS INC stock?
The consensus rating for OVID THERAPEUTICS INC (OVID) is 87.1429 / 100 . This indicates that analysts generally have a positive outlook on the stock.